Moleculin Biotech (MBRX) Scheduled to Post Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) will announce its earnings results after the market closes on Friday, May 10th. Analysts expect the company to announce earnings of ($3.59) per share for the quarter.

Moleculin Biotech Stock Down 3.5 %

NASDAQ:MBRX opened at $4.91 on Thursday. The stock’s fifty day moving average is $6.19 and its two-hundred day moving average is $7.86. Moleculin Biotech has a 52 week low of $4.28 and a 52 week high of $15.75. The stock has a market capitalization of $10.93 million, a price-to-earnings ratio of -0.36 and a beta of 1.85.

Analyst Ratings Changes

A number of research analysts have commented on MBRX shares. StockNews.com started coverage on Moleculin Biotech in a research note on Tuesday. They set a “sell” rating on the stock. Roth Mkm reiterated a “buy” rating and issued a $40.00 price objective on shares of Moleculin Biotech in a research note on Friday, April 12th. Finally, Maxim Group reduced their price objective on Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 26th.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.